demo · 166 papers with claims · 148 for outreach · 2 old · 16 reviews
<2016
Filtered out
Co-opting signalling molecules enables logic-gated control of CAR T cells
Activation-inducible CAR expression enables precise control over engineered CAR T cell function
LINKing signaling domains to enhance CAR T cells
DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation
Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
OC41 - Glucocorticoid inhibition enables mono- and bispecific CAR-T cells to overcome immunotherapeutic resistance in ad
IMMU-74. Novel screening method to identify potent immune-inspired inhibitors for NOT-gated CAR T cells to suppress on-t
Figure 2 from Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Figure 2 from Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Logic-Gated CAR T Cells Enhance Survival and Reduce On-Target Toxicity.
Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes
Hurdles to breakthrough in CAR T cell therapy of solid tumors
Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocy
BASECAMP-1: An approach to improve patient screening efficiency and to provide large datasets for precision medicine cli
Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte an
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Design and characterization of multiplex gene-edited CAR-T cells resistant to orthogonal immunosuppressive pathways with
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Toward the clinical development of synthetic immunity to cancer
T cell circuits that sense antigen density with an ultrasensitive threshold
The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019
Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity
Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic s
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols d
280 Novel AND-gated LINK CAR-T cells demonstrate improved safety compared to 2nd-generation CAIX CAR-T cells for the tre
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity
To go or not to go? Biological logic gating engineered T cells
Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations
Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism
589 BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Se
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
CAR‐T Cell Therapy in Cancer: Tribulations and Road Ahead
CAR T Cell Therapy for Solid Tumors
Data from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
Abstract LB092: Identification of target antigens for logic-gated CAR-T therapeutics for the treatment of clear cell ren
Abstract 6118: Engineering p95HER2 CAR T cells for the treatment of HER2-positive tumors
Geometric parameters that affect the behavior of logic-gated CAR T cells
Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironme
Data Sheet 1_Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor m
Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer
A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Advances in Cell and Immune Therapies for Melanoma
Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours
Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe
Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
Synthetic Notch-Receptor-Mediated Transmission of a Transient Signal into Permanent Information via CRISPR/Cas9-Based Ge
Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
When CAR Meets Stem Cells
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Car T Cells in Solid Tumors: Overcoming Obstacles
Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer I
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)
Engineering Next-Generation CAR-T Cells for Better Toxicity Management
Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics
CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells
CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects
The progress of CAR-T therapy in cancer and beyond
Faculty Opinions recommendation of T cell circuits that sense antigen density with an ultrasensitive threshold.
Migratory Engineering of T Cells for Cancer Therapy
Chimeric Antigen Receptor T-Cell Therapy
CAR T cell-induced systemic cytokine toxicity: current understanding and innovative designs
Boolean Logic-Gated CAR T Cells with TCR Mimic Recognition Overcome Critical Antigen Targeting Barrier in Solid Tumors
Reprogramming T Cells to Interrogate Intracellular Disease Signatures
Engineering T cells with diverse mechanisms for improved tumor recognition precision
Rewiring signaling responses to soluble extracellular cues for T-cell therapies and beyond
Tuning the SUPRA CAR to differentiate high/low Her2 levels
Context-specific synthetic T cell promoters from assembled transcriptional elements
Novel Adapter CAR-T cell Technology for precisely controllable Multiplex Cancer Targeting
The Landscape of Receptor-Mediated Precision Cancer Combination Therapy: A Single-Cell Perspective
Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
PRECLINICAL MOUSE MODELS IN ADOPTIVE CELL THERAPIES OF CANCER
Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current Clinical Trials and Future Directions
Solid tumours: Building bridges to CAR‐T success
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Inc
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Implementing Logic Gates for Safer Immunotherapy of Cancer
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy
Switching on the green light for chimeric antigen receptor T‐cell therapy
Light‐Controllable Binary Switch Activation of CAR T Cells
Boolean logic in synthetic biology and biomaterials: Towards living materials in mammalian cell therapeutics
CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy
The antigen‐binding moiety in the driver's seat of CARs
Chimeric antigen receptor transduced T cells: Tuning up for the next generation
CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies
Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
From antibodies to living drugs: Quo vadis cancer immunotherapy?
Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells
Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer
Engineering transcriptional regulation for cell-based therapies
CAR T‐cell therapy of solid tumors
Engineering cell sensing and responses using a GPCR-coupled CRISPR-Cas system
Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
Remote control of CAR T cell therapies by thermal targeting
A functional screening platform for engineering chimeric antigen receptors with reduced on-target, off-tumour activation
Design and modular assembly of synthetic intramembrane proteolysis receptors for custom gene regulation in therapeutic c
Clinically-driven design of synthetic gene regulatory programs in human cells
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Identification of cancer-specific cell surface targets for CAR-T cell therapy
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors
A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker
De novo -designed minibinders expand the synthetic biology sensing repertoire
Revealing Facts About CAR-T Cell Therapy
Precise surface functionalization of PLGA particles for human T cell modulation
From barriers to novel strategies: smarter CAR T therapy hits hard to tumors
Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects
SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics
huahan@fmmu.edu.cn
The Notch signaling pathway: a potential target for cancer immunotherapy
SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics
m-sadelain@ski.mskcc.org
CAR T cell design: approaching the elusive AND-gate
aposey@pennmedicine.upenn.edu
Driving cars to the clinic for solid tumors
stuhler_g@ukw.de
On-target restoration of a split T cell-engaging antibody for precision immunotherapy
bramsonj@mcmaster.ca
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
Engineering advanced logic and distributed computing in human CAR immune cells
sbzhou@jhmi.edu
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
xbzhang@hnu.edu.cn
Microenvironment-confined kinetic elucidation and implementation of a DNA nano-phage with a shielded internal computing
m-kawahara@nibiohn.go.jp
Rational design of heterodimeric receptors capable of activating target signaling molecules
alexandre.juillerat@cellectis.com
An oxygen sensitive self-decision making engineered CAR T-cell
eytan.ruppin@nih.gov.
The Landscape of Receptor-Mediated Precision Cancer Combination Therapy: A Single-Cell Perspective
sai.reddy@bsse.ethz.ch
Discovery and validation of novel human genomic safe harbor sites for gene and cell therapies
wendell.lim@ucsf.edu
T cell circuits that sense antigen density with an ultrasensitive threshold
xujianqing@shaphc.org.cn
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces t
Coopting T cell proximal signaling molecules enables Boolean logic-gated CAR T cell control
xjgao@stanford.edu
Compact Programmable Control of Protein Secretion in Mammalian Cells
hus@smmu.edu.cn.
Synthetic Cellular Immunity based on CAR repertoire for Human Immunotherapy
wangzhc6@mail.sysu.edu.cn
A long way to the battlefront: CAR T cell therapy against solid cancers
liym@lzu.edu.cn
Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
m.bachmann@hzdr.de
Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells
flehmann@celyad.com
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
hj-jin@hotmail.com.
New Strategies for the Treatment of Solid Tumors with CAR-T Cells